IDEXX Laboratories, Inc. (IDXX)
IDEXX to Release Q2 Earnings: What's in Store for the Stock?
IDXX eyes a Q2 earnings jump with CAG growth, global pricing gains, and momentum in water and software segments.
IDEXX Laboratories: A Business With Strong Fundamentals
I rate IDEXX Laboratories a buy, driven by a lasting surge in pet ownership and IDXX's leadership in veterinary diagnostics. New platforms like inVue Dx and Cancer Dx provide additional growth drivers, with strong early adoption and potential for margin expansion. IDXX's recurring revenue model, robust retention, and expanding high-margin consumables base support sustained revenue and earnings growth.
Idexx (IDXX) is an Incredible Growth Stock: 3 Reasons Why
Idexx (IDXX) could produce exceptional returns because of its solid growth attributes.
Will Idexx (IDXX) Beat Estimates Again in Its Next Earnings Report?
Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
IDEXX Laboratories: Growth Remains Despite Weak Clinical Visits
IDEXX Laboratories, Inc. delivered strong Q1 FY25 results with 4.7% organic revenue and 7% adjusted EPS growth, despite weak US clinical visits. I see catalysts ahead: potential U.S. tax cuts, normalization of consumer spending, and robust pricing power supporting profit growth. Management guides for 6%-9% organic revenue and 8%-12% adjusted EPS growth in FY25; I model 8.2% revenue growth and margin expansion.
Is IDEXX Laboratories (IDXX) Outperforming Other Medical Stocks This Year?
Here is how Idexx Laboratories (IDXX) and AngioDynamics (ANGO) have performed compared to their sector so far this year.
Compared to Estimates, Idexx (IDXX) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for Idexx (IDXX) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Idexx Laboratories (IDXX) Beats Q1 Earnings Estimates
Idexx Laboratories (IDXX) came out with quarterly earnings of $2.96 per share, beating the Zacks Consensus Estimate of $2.92 per share. This compares to earnings of $2.81 per share a year ago.
Why Idexx Laboratories (IDXX) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Seeking Clues to Idexx (IDXX) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Idexx (IDXX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.
Idexx Laboratories (IDXX) Reports Next Week: Wall Street Expects Earnings Growth
Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IDXX Gears Up for Q1 Earnings: What to Expect From the Stock?
IDEXX Laboratories' first-quarter 2025 performance is expected to have benefited from a strong execution against strategic priorities.
